

Jack Khouri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3580033/publications.pdf>

Version: 2024-02-01

41
papers

258
citations

1162367

8
h-index

1058022

14
g-index

41
all docs

41
docs citations

41
times ranked

394
citing authors

#	ARTICLE	IF	CITATIONS
1	The Association of Pre-Transplant Adiposity with Autologous Hematopoietic Stem Cell Transplantation Outcomes in Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S412.	0.6	0
2	Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 1031-1033.	1.3	1
3	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3991-3995.	2.5	5
4	Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. <i>Cancer Research</i> , 2021, 81, 713-723.	0.4	24
5	Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , 2021, 62, 735-738.	0.6	5
6	DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Seminars in Hematology</i> , 2021, 58, 45-55.	1.8	8
7	Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. <i>British Journal of Haematology</i> , 2021, 193, 1213-1219.	1.2	25
8	Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. <i>Blood Cancer Journal</i> , 2021, 11, 121.	2.8	6
9	Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature. <i>Annals of Hematology</i> , 2021, 100, 2155-2172.	0.8	4
10	Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2021, 21, 30-45.	0.2	11
11	Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Tj ETQq1 1 0.784314 rgBT /Over	3.4	28
12	Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4941-4960.	1.0	4
13	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1344-1352.	0.6	7
14	Updated Organ Response Results of an Open-Label Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis Receiving Anti-Plasma Cell Therapy. <i>Blood</i> , 2021, 138, 2724-2724.	0.6	3
15	A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2757-2757.	0.6	1
16	Advance Care Planning in Hematopoietic Stem Cell Transplant Recipients: A Survey of Providers in a Blood & Marrow Transplant Program. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S78.	2.0	0
17	Toxicity Analysis of Busulfan Pharmacokinetic Guided Therapeutic Dose Monitoring for Myeloablative Conditioning Regimens with Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S388-S389.	2.0	0
18	Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e137-e143.	0.2	12

#	ARTICLE	IF	CITATIONS
19	Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis. <i>Blood</i> , 2020, 136, 21-21.	0.6	9
20	Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the <i>PRISM</i> score. <i>Blood</i> , 2020, 136, 29-30.	0.6	2
21	Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel. <i>Blood</i> , 2020, 136, 38-39.	0.6	2
22	Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
23	Daratumumab proves safe and highly effective in <sc>AL</sc> amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 342-344.	1.2	46
24	Pomalidomide-based maintenance post-autologous hematopoietic cell transplantation in multiple myeloma: a case series. <i>Annals of Hematology</i> , 2019, 98, 2457-2459.	0.8	4
25	Body mass index does not impact hematopoietic progenitor cell mobilization for autologous hematopoietic cell transplantation. <i>Journal of Clinical Apheresis</i> , 2019, 34, 638-645.	0.7	6
26	Progression with clinical features is associated with worse subsequent survival in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 439-445.	2.0	12
27	Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e374-e376.	0.2	1
28	A Phase 1/2 Trial of Low-Dose Continuous Azacitidine in Combination with Lenalidomide and Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e262-e263.	0.2	0
29	Real World Data on the Safety and Efficacy of Pomalidomide as a Single Agent and in Combination with Corticosteroids in Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e240-e241.	0.2	0
30	Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis. <i>Blood</i> , 2019, 134, 4452-4452.	0.6	3
31	External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2019, 134, 3148-3148.	0.6	1
32	Monoclonal gammopathy of undetermined significance: A primary care guide. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 39-46.	0.6	8
33	Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status. <i>Blood</i> , 2019, 134, 5248-5248.	0.6	1
34	Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis. <i>Blood</i> , 2019, 134, 1838-1838.	0.6	1
35	A Phase I Trial of Venetoclax in Combination with BEAM Conditioning Chemotherapy (V-BEAM) with Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 5705-5705.	0.6	0
36	The Biological Inferences from the Ranking of SF3B1 Mutations in the Clonal Hierarchy of Myeloid Neoplasia. <i>Blood</i> , 2019, 134, 5411-5411.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days. <i>Journal of Clinical Apheresis</i> , 2018, 33, 303-309.	0.7	6
38	Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1899-1899.	0.6	3
39	Advances in delivery of ambulatory autologous stem cell transplantation for multiple myeloma. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 361-365.	0.5	14
40	Hepatitis B (HBV) Screening in Patients Receiving Rituximab: A Comprehensive Analysis Including Comparison of Adherence By Oncologists and Non-Oncologists. <i>Blood</i> , 2014, 124, 2595-2595.	0.6	0
41	Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review. <i>European Journal of Haematology</i> , 0, , .	1.1	3